Three-year update outcomes of the first chimeric antigen receptor-T therapy for children and young adults with relapsed/refractory acute lymphoblastic leukemia

Hideki Nakayama

doi:10.21037/tp-23-535

Three-year update outcomes of the first chimeric antigen receptor-T therapy for children and young adults with relapsed/refractory acute lymphoblastic leukemia

Transl Pediatr. 2024 Apr 30;13(4):535-536. doi: 10.21037/tp-23-535. Epub 2024 Apr 8.

Author

Hideki Nakayama¹

Affiliation

¹ Department of Pediatrics, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.

No abstract available

Keywords: Tisagenlecleucel; chimeric antigen receptor-T cell therapy (CAR-T cell therapy); relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL).

Publication types

Editorial
Comment